stocks logo

KURA Valuation

Kura Oncology Inc
$
5.770
+0.140(+2.490%)
  • Overview
  • Forecast
  • Valuation

KURA Relative Valuation

KURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KURA is overvalued; if below, it's undervalued.
Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.06
P/B
Median3y
2.33
Median5y
2.70
27.76
FCF Yield
Median3y
-11.29
Median5y
-9.44

Competitors Valuation Multiple

The average P/S ratio for KURA's competitors is 6.17, providing a benchmark for relative valuation. Kura Oncology Inc Corp (KURA) exhibits a P/S ratio of 3.60, which is -41.71% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

FAQ

arrow icon

Is Kura Oncology Inc (KURA) currently overvalued or undervalued?

Kura Oncology Inc (KURA) is now in the Fair zone, suggesting that its current forward PS ratio of 3.60 is considered Fairly compared with the five-year average of 50.63. The fair price of Kura Oncology Inc (KURA) is between to according to relative valuation methord.
arrow icon

What is Kura Oncology Inc (KURA) fair value?

arrow icon

How does KURA's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Kura Oncology Inc (KURA) as of Apr 12 2025?

arrow icon

What is the current FCF Yield for Kura Oncology Inc (KURA) as of Apr 12 2025?

arrow icon

What is the current Forward P/E ratio for Kura Oncology Inc (KURA) as of Apr 12 2025?

arrow icon

What is the current Forward P/S ratio for Kura Oncology Inc (KURA) as of Apr 12 2025?